Abstract: Compounds of formula I, in which LA, LB, LC, ring A, ring B, RA, RB, RC, RD, RE and RF are defined in the description, and which are protein kinases inhibitors. The invention also relates to pharmaceutical compositions containing said compounds and also to the use of those compounds for treatment and/or prevention of diseases related with aberrant protein kinase activity.
Type:
Grant
Filed:
June 30, 2014
Date of Patent:
July 4, 2017
Assignees:
LIMITED LIABILITY COMPANY “NATIONAL PHARMACEUTICAL TECHNOLOGIES”, LIMITED LIABILITY COMPANY “PHARMENTERPRISES”